Date Hour Room Track
28th November,2017 12 am Track 1

To what extent does the coordination of the activities of funding agencies, academic researchers, companies, regulatory bodies, and patient advocacy organizations and partnerships with the European Research Infrastructures maximises the collective impact of global investments in rare diseases research ?


Continue your tour